A Phase 3, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE 001)
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2019
At a glance
- Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms RATIONALE001
- Sponsors Celgene Corporation
- 06 Dec 2018 Planned initiation date (Estimated date of first participant enrollement) changed from 26 Nov 2018 to 7 Jan 2019.
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 22 Nov 2018 New trial record